DTI vs. CLB: Which Stock Is the Better Value Option?

WMB's Q2 earnings and revenues miss estimates but rise year over year as it raises 2026 EBITDA guidance and expands its gas network.

FANG tops Q2 earnings and revenue estimates as higher realized oil prices, production growth and a boosted buyback plan underscore a strong quarter.

Core Laboratories stock looks cheaper after a 47.1% six-month selloff, but falling earnings and geopolitical pressure keep the near-term case cautious.

CLB's Q2 earnings top estimates despite lower revenues and profit as Production Enhancement strength offsets Reservoir Description weakness.

Core Laboratories (CLB) delivered earnings and revenue surprises of +37.50% and -2.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CLB's Q2 may reflect resilient international activity and tariff insulation, but weaker reservoir description results and higher costs could weigh.

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.